FII-INSTITUTE
7.9.2021 23:55:11 CEST | Business Wire | Press release
Population projections stress the need for sustainable living on our planet and on others. FII Institute announces today an investment in Interstellar Lab, a space technology company designing closed loop biodomes for sustaining life on Earth, the moon, and Mars.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210907005919/en/
FII Institute is a global non-profit foundation with an investment arm and one agenda: Impact on Humanity. The $500,000 USD equity investment is a part of Interstellar Lab's latest $3M USD Seed Round and builds on FII Institute's commitment to catalyze globally relevant, real-world solutions in Artificial Intelligence and Robotics, Education, Healthcare and Sustainability. Through the investment, the Institute will fund the development of, and leverage, AI simulation-based designs to tackle Earth’s most pressing environmental issues, paving the way to solutions in waste management, zero-impact living and resource-conscious agriculture.
“Climate change is a real emergency for Earth, and we only have a small window to bring about positive change. We are developing a new framework for sustainable living on Earth and a testbed for future space missions,” Barbara Belvisi, Founder and CEO, Interstellar Lab said. “Working with investors like FII Institute advances Interstellar Lab’s mission to support human life sustainably on Earth, the moon and Mars by generating and recycling food, water and air.”
FII Institute CEO Richard Attias said, "Space sector growth is creating new opportunities for advanced research and solutions in sustainability. Inspired by the design challenge of human settlement on Mars, Interstellar Lab has forged an innovative approach to sustaining life in the absence of the abundance taken for granted here on Earth. We are very pleased to support the technologies that will help reduce the burden on our planet and prepare us for the future."
This marks the third FII Institute investment this year following announcements to back Lilium, an electric-powered aircraft reducing the carbon impact of regional travel, and Red Sea Farms, AgTech making it possible to grow food using saltwater. With an inclusive agenda built on three pillars – THINK, XCHANGE, ACT – FII Institute empowers the brightest minds to leverage scientific innovation for positive change, brings leading solutions to reality through investment, and calls for global collaboration in the service of humanity.
About FII Institute (Future Investment Initiative Institute)
FII Institute is a global non-profit foundation with an investment arm and one agenda: Impact on Humanity. Committed to Environmental, Social and Governance (ESG) principles, we foster the brightest minds and transform ideas into real-world solutions.
When decision makers, investors and an engaged generation of youth come together, energized and ready for change, we harness that energy into three pillars – THINK, XCHANGE, ACT – and invest in the innovations that make a difference to lives globally.
About Interstellar Lab
Interstellar Lab is developing and building closed-loop sustainable living systems on Earth and in space. The company focuses on creating space-grade food production systems and habitat modules. The aim is double: to provide solutions regarding the current climate crisis and the need of new food production systems on Earth, and to develop closed-loop life support systems for lunar missions in the context of NASA’s Artemis Program and in the future for Mars exploration.
*Source : AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005919/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom